CiVi Biopharma
Dr. Ørum brings more than 25 years of experience in every aspect of creating, building, leading and exiting successful biotechnology companies.
Dr. Ørum started his biotech career at PNA Diagnostics A/S in 1993, serving as chief scientific officer from 1993 to 1999. During his tenure, the company was sold to Boehringer Mannheim in 1994 and later to Hoffman-La Roche in 1997. In 1996, Dr. Ørum co-founded Exiqon A/S, a nucleic acid diagnostics company that was listed on the Copenhagen Stock Exchange in 2007 (CSE:EXQ).
This person is not in any offices
CiVi Biopharma
CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company's research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi’s innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases.